In part 2 of this Frontline Forum series, John M. Strasswimmer, MD, PhD; Andrew H. Weinstein, MD; Neal Bhatia, MD; Laura Ferris, MD; and Aaron S. Farberg, MD, discuss solutions for managing and treating patients with basal cell carcinoma.
Dermatology Times Staff
Advertisement
Articles by Dermatology Times Staff
Click here to answer this week's poll.
In part 1 of this Frontline Forum series, John M. Strasswimmer, MD, PhD; Andrew H. Weinstein, MD; Neal Bhatia, MD; Laura Ferris, MD; and Aaron S. Farberg, MD, discuss solutions for managing and treating patients with basal cell carcinoma.
Click here to answer this week's poll.
Let us know what content you want to see from RAD.
Click here to answer this week's poll.
Click here to answer this week's poll.
Click here to answer this poll related to Rosacea Awareness Month.
Click here to answer this week's poll.
Click here to answer this week's poll.
Click here to answer this week's poll.
Answer our new poll leading up to AAD 2023.
Click here to answer our new AAD 2023 poll.
Click here to answer this week's poll.
Interested in sharing your perspectives as a woman in dermatology? Contact us.
Click here to answer this week's poll.
Click here to answer this week's poll.
Click here to answer this week's poll.
Click here to answer this week's poll.
Click here to answer this week's poll.
Click here to answer this week's poll.
Click here to answer this week's poll.
Click here to answer this week's poll.
Click here to answer this week's poll.
Click here to answer this week's poll.
Click here to answer this week's poll.
Click here to answer this week's poll.
Click here to answer this week's poll.
Click here to answer this week's poll.
Click here to answer this week's poll.
Advertisement
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 3 Data Position Zasocitinib as a Potential New Oral Option for Psoriasis
2
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
3
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
4
Topicals Demonstrate Targeted Control Across 3 Distinct Atopic Dermatitis Cases
5